DEA Ends Exemptions for Ghost Butalbital Products
Published Date: 5/26/2026
Proposed Rule
Summary
The DEA wants to remove certain inactive butalbital prescription products from their special exemption list because these products aren’t available anymore or the companies behind them are gone. This means these products will now be treated like controlled substances, not exempt ones. If you have thoughts, you’ve got until June 25, 2026, to speak up—no money changes for active products, just a cleanup of the list!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13992 — Timothy Genetta, D.O.; Decision and Order
Dr. Timothy Genetta from Ohio lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he must stop prescribing or handling these drugs immediately, with no money or timing benefits for him.
2026-13991 — Ruth Jones, D.O.; Decision and Order
Ruth Jones, D.O., tried to get a DEA registration but was denied because she was convicted of serious drug-related crimes and banned from federal health programs. She missed the deadline to ask for a hearing, so the case was closed against her. This means she can’t legally handle controlled substances, affecting her medical practice and career.
2026-13989 — Mark Allen, D.D.S.; Decision and Order
Mark Allen, D.D.S., lost his DEA registration because he no longer has permission to handle controlled substances in Oklahoma. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting his dental practice and any related income.
2026-13988 — Frederick Tanzer, M.D.; Decision and Order
Dr. Frederick Tanzer from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means Dr. Tanzer can’t legally prescribe or handle certain drugs anymore, effective immediately.
Previous / Next Documents
Previous: 2026-10377 — Regulation D: Reserve Requirements of Depository Institutions
The Federal Reserve is proposing a change to how it treats special-purpose payment accounts, called Payment Accounts, by not paying interest on the money held in them. This update affects banks with master accounts and these new Payment Accounts but won’t change reserve requirements, which stay at zero. If you want to share your thoughts, you have until July 27, 2026, to comment!
Next: 2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.